Business and Presentation (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended				1 Months Ended	3 Months Ended	9 Months Ended			9 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014 Research and Development Arrangement [Member]	Jun. 25, 2014 Convertible Debt Facility [Member]	Mar. 31, 2014 Convertible Debt Facility [Member]	Sep. 30, 2014 Arthrex [Member] Accounts Receivable [Member]	Sep. 30, 2014 Aldagen Inc [Member]	Sep. 30, 2014 Angel [Member]	Sep. 30, 2014 Angel [Member] Arthrex [Member]	Sep. 30, 2014 Non United States [Member]	Sep. 30, 2013 Non United States [Member]	Sep. 30, 2014 Non United States [Member]	Sep. 30, 2013 Non United States [Member]
Percentage Of Product Sales														50.00%	6.00%	30.00%	13.00%
Concentration Risk, Percentage													100.00%
Percentage of accounts receivable										41.00%
Allowance for Doubtful Accounts Receivable		$ 58,000		$ 58,000		$ 16,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net											422,000	707,000
Income Tax Expense (Benefit)		4,645	4,890	13,935	14,670
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount				224,287,504	28,207,642
Convertible Debt									35,000,000
Proceeds from Convertible Debt								26,000,000	9,000,000
Proceeds From Issuance Of Common Stock And Warrants									2,000,000
Repayments of Notes Payable				6,201,143	570,000				5,900,000
Repayments of Convertible Debt									340,000
Debt Conversion, Converted Instrument, Amount				3,067,423					3,100,000
Cash		20,000,000		20,000,000
Deferred Licensing Revenue		1,542,000		1,542,000
Licenses Revenue		100,594	67,063	301,783	67,063
Medical Device Excise Tax Percentage	2.30%
Minimum Cash Balance		5,000,000		5,000,000
Restructuring Reserve		$ 486,000		$ 486,000			$ 438,000